Efficacy of Amifostine in Treating Patients with Idiopathic Thrombocytopenia Purpura

Cell Biochemistry and Biophysics

Volumn 59, Issue 1, 2011, Pages 7-12

  Fan, Hui ^a   Zhu, Hong Li ^a   Li, Su Xia ^a   Lu, Xue Chun ^a   Zhai, Bing ^a   Guo, Bo ^a   Yao, Shan Qian ^a   Liu, Yang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Amifostine; Idiopathic thrombocytopenia purpura; Myelodysplastic syndrome; Platelets

Indexed keywords

HELICOBACTER PYLORI;

EID: 78650417942     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-010-9100-5     Document Type: Article

References (20)

1. Cines, D. B., & McMillan, R. (2005). Management of adult idiopathic thrombocytopenic purpura. Annual Review of Medicine, 56, 425-442.
2. McMillan, R., Wang, L., Tomer, A., Nichol, J., & Pistillo, J. (2004). Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 103, 1364-1369.
3. Stevens, W., Koene, H., Zwaginga, J. J., & Vreugdenhil, G. (2006). Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Netherlands Journal of Medicine, 64, 356-363.
4. Bussel, J. B. (2009). Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematology/Oncology Clinics of North America, 23, 1329-1341.
5. Rodeghiero, F. (2008). First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. European Journal of Haematology. Supplementum, 69, 19-26.
6. Culy, C. R., & Spencer, C. M. (2001). Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs, 61, 641-684.
7. Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., et al. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood, 95, 1580-1587.
8. Li, S. X., Zhu, H. L., Lu, X. C., Fan, H., Yao, S. Q., et al. (2007). Amifostine used in the treatment of patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 86-90.
9. Lu, X. C., Zhu, H. L., Yao, S. Q., Fan, H., Zhuang, X. M., et al. (2005). Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, 440-442.
10. Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995-1008.
11. Newland, A. (2008). Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology. Supplementum, 69, 27-33.
12. Ben-Yehuda, D., Gillis, S., & Eldor, A. (1994). Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematologica, 91, 1-6.
13. Michel, M., Cooper, N., Jean, C., Frissora, C., & Bussel, J. B. (2004). Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 103, 890-896.
14. Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., et al. (2006). AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672-1681.
15. Dimopoulou, M. N., Gandhi, S., Ghevaert, C., Chakraverty, R., Fielding, A., et al. (2007). Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplantation, 40, 605-606.
16. Marcu, L. G. (2009). The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. European Journal of Cancer Care (England), 18, 116-123.
17. Winczura P, Jassem J (2009) Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev.
18. Santini, V., & Giles, F. J. (1999). The potential of amifostine: From cytoprotectant to therapeutic agent. Haematologica, 84, 1035-1042.
19. Viniou, N., Terpos, E., Galanopoulos, A., Kritikou-Griva, E., Akel, S., et al. (2002). Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Annals of Hematology, 81, 182-186.
20. Fan, H., Zhu, H. L., Yao, S. Q., Lu, X. C., Zhuang, X. M., et al. (2006). Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 14, 301-303.